Rezolute, Inc. (RZLT): Form 8-K filed 2026-11-13
- Accepted by EDGAR
- 2026-11-13 06:27 ET
- Event date
- 2026-11-13
- Accession no.
- 0001104659-26-126502
- Original filing
- SEC EDGAR filing index
AI summary of the filing text. It can contain mistakes; the original filing is authoritative.
Rezolute reports preliminary primary endpoint achievement in Phase 3 upLIFT study
Rezolute reported that its ongoing Phase 3 upLIFT study of ersodetug in tumor hyperinsulinism achieved its primary efficacy endpoint based on preliminary results. Among 16 participants, 13 met the responder criterion, including 12 who discontinued IV glucose completely. Completed-study results, including statistical analysis of the primary endpoint, are expected by mid-December 2026.
- Among 16 participants, 13 met the responder criterion of at least a 50% reduction from baseline in glucose infusion rate.
- Of the responders, 12 achieved complete discontinuation of IV glucose.
- Three participants remain in the pivotal period, including two who have not yet met the responder criterion.
- Ersodetug was well-tolerated to date, with no drug-related safety findings attributed to it.
product
Items reported
- Item 7.01: Regulation FD Disclosure
The company is making information public under Regulation FD, which requires broad public disclosure of material information shared with certain market participants. Investor presentations and press releases are common. Like Item 2.02, this information is generally "furnished" rather than "filed". - Item 8.01: Other Events
A voluntary disclosure of an event the company considers important to security holders that no other Item covers, such as a dividend declaration, a buyback program, litigation updates or product news. - Item 9.01: Financial Statements and Exhibits
Lists the financial statements, pro forma information and exhibits filed with the report. It almost always accompanies another Item and is rarely news on its own.
Documents
| Type | Description | Document |
|---|---|---|
| 8-K | FORM 8-K | tm2627558d10_8k.htm |
| EX-99.1 | EXHIBIT 99.1 | tm2627558d10_ex99-1.htm |
The summary above was generated by AI from the filing text and checked automatically against it. Read the original documents on SEC EDGAR. How to read an 8-K.